Quick Answer
NovoCure Ltd reported Long Term Debt of $568.82 million for the year ending 2023.
- NovoCure Ltd showed an increase of +0.6% in Long Term Debt from 2022 to 2023.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 22, 2024.
- XBRL data for this metric is available from 2014 to 2023 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $24.55 million | Q1 2016: $23.19 million | Q2 2016: $23.29 million | Q3 2016: $95.97 million | Q1 2017: $96.49 million | Q2 2017: $96.77 million | Q3 2017: $97.05 million | Q1 2018: $149.16 million | Q2 2018: $149.20 million | Q3 2018: $149.23 million | Q1 2019: $149.31 million | Q2 2019: $149.34 million | Q3 2019: $149.38 million | Q1 2020: $149.47 million | Q2 2020: $149.51 million | Q3 2020: $0.00 | Q1 2021: $559.58 million | Q2 2021: $560.56 million | Q3 2021: $561.39 million | Q1 2022: $563.03 million | Q2 2022: $563.85 million | Q3 2022: $564.68 million | Q1 2023: $566.32 million | Q2 2023: $567.15 million | Q3 2023: $567.99 million | Q4 2023: $568.82 million | Q1 2024: $569.65 million.
- Historical annual values: Fiscal year 2023: $568.82 million | Fiscal year 2022: $565.51 million | Fiscal year 2021: $562.22 million | Fiscal year 2020: $429.91 million | Fiscal year 2019: $149.42 million | Fiscal year 2018: $149.27 million | Fiscal year 2017: $97.34 million | Fiscal year 2016: $96.23 million | Fiscal year 2015: $23.10 million | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: